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showed improved safety and higher accuracy. Our results indicate that 
intraoperative US may have important staging implication. 
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Background: Surgery is the gold standard for cure in resectable Non-
Small-Cell Lung Cancer (NSCLC). Pneumonectomy and lobectomy 
are performed along with mediastinal lymph node dissection to allow 
pTNM staging. In other tumor types including colon and gastric cancer, 
it has been demonstrated that the number of examined lymph node is 
an independent prognostic factor of survival, whatever the lymph node 
involvement. We retrospectively analyzed 218 patients with a totally 
resected NSCLC and looked at the prognostic value of the number of 
lymph nodes examined on the resected specimen. 
Methods: Consecutive cases from 01/2001 to 12/2004 included 81% 
men, median age 61, Squamous histology 50%, Adenocarcinoma 39%. 
There were 44% pTNM stage I, 29% stage II and 27% stage III, (54% 
pN0, 30% pN1 and 16% pN2), median follow-up 38 months. Surgery 
consisted in pneumonectomy (33%), lobectomy or bilobectomy (67%). 
Only 18 patients (8.6%) received adjuvant chemotherapy.
Results: The median number of lymph nodes examined was 7 (1-48) 
(pneumonectomy, median of examined lymph nodes 10, lobectomy/
bilobectomy, 6 examined lymph nodes). Three groups were deﬁned 
according to the number of examined lymph nodes to assess a possible 
prognostic value: 0-4 (group 1), 5-8 (group 2), 9 or more(group 3). In 
the overall population, no difference was seen among the three groups 
on Relapse-Free Survival (RFS, p=0.48), Lung cancer Speciﬁc Survival 
(LCSS, p=0.44) and Overall Survival (OS, P=0.63). In stage pN1, the 
number of examined lymph nodes if less than 5 had a signiﬁcant impact 
on RFS (p=0.0003), on OS (p=0.014), and on LCSS (p=0.028). No 
difference was seen in stage pN0 and pN2. Based on the present study, 
patients resected for Stage pN1 with less than 5 lymph nodes examined 
on the resected specimen have a poor outcome, behaving as patients 
with stage pN2 and actually may be understaged: RFS 7.2 vs 7.6 
months, LCSS 23.5 vs 18.7 months, OS 21.6 vs 18.5 months in pN2 vs 
pN1 with less than 5 examined lymph nodes respectively. 
Conclusion: A minimum of 5 lymph nodes should be recommended 
for pathologic examination to provide proper staging in stage pN1 
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Purpose: Operative stress can alter the blood levels of various physi-
ologically active substances (cytokines, growth factors, etc.), and thus 
potentially affect cancer cell proliferation. How the combination of 
changes in blood levels of these substances affects cancer cells has not 
been adequate addressed. In an in vitro study we previously reported 
that human serum obtained immediately after lung resection surgery 
stimulated lung cancer cell proliferation compared to that obtained 
before surgery. Here we investigated the time course of the stimulation 
capacity of serum for cancer cell proliferation in the early postoperative 
period.
Methods: The subjects were 10 patients undergoing lung cancer surgery. 
Blood was sampled from each subject immediately before surgery and 
immediately, one day, one week, and two weeks after surgery. Serum 
derived from each blood sample was frozen and stored. EBC-1, a human 
NSCLC culture cell line, was used for the study. Cells were exposed to 
serum (collected at varying points of time before and after surgery) at a 
concentration of 10% for 48 hours. MTT assay was conducted thereafter 
to evaluate cell proliferation, with absorbance (O.D.) measured at 540 
nm (control: 630 nm) using a microplate reader. The percent stimulation 
of cell proliferation with postoperative serum compared with control 
(preoperative) serum was calculated using the formula 100 x (postopera-
tive O.D. - preoperative O.D.)/preoperative O.D.
Results: Serum collected at each time point (immediately, one day, one 
week, and two weeks) after surgery signiﬁcantly stimulated the pro-
liferation of EBC-1 compared to preoperative serum. Serum collected 
immediately after surgery showed the highest percent stimulation of 
cell proliferation, and this effect tended to decrease gradually with time 
after surgery. However, even serum collected two weeks after surgery 
still signiﬁcantly stimulated cell proliferation compared to preoperative 
serum. 
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Background: The aim of the study was to identify the common factors 
which affect survival of surgically resected non-small cell lung cancer 
(NSCLC) patients with N1 and N2 disease.
Methods: A retrospective review was performed in NSCLC patients 
who underwent primary surgical resection from Jan 2000 to Sep 2006. 
The inclusion criteria were patients with 1) pathologically conﬁrmed 
N1 and N2 disease, 2) pathologic T1 to T3 disease, 3) no history of 
neoadjuvant chemotherapy, and 4) complete mediastinal lymphad-
enectomy. During the study period 468 NSCLC patients with nodal 
metastasis were operated on in our hospital. According to the selection 
criteria, 281 patients (60.0%) were included in the study. There were 
132 patients with N1 disease (N1 group) and 149 patients with N2 dis-
ease (N2 group). The median follow-up period was 22 months (1 ~ 81 
months) and complete follow-up was possible in 269 patients (95.7%).
Results: Lobectomy was performed in 195 patients (69.4%), bilobec-
tomy in 43 (15.3%) and pneumonectomy in 43 (15.3%). Complete 
resection was possible in 274 patients (97.5%) and operative mortality 
